VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ASCO 2020 | CDKN2A and TP53 mutation in HPV-negative HNSCC

Barbara Burtness • 28 May 2020
ASCO 2020
Head and Neck Cancer Trastuzumab

Barbara Burtness, MD, of Yale Cancer Center, New Haven, CT, discusses the predicitive value of TP53 and CDKN2 mutations in determining tumor mutational burden in HPV negative head and neck squamous cell carcinoma. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

More from Barbara Burtness

3:08
KEYNOTE-048: pembrolizumab monotherapy for frontline R/M HNSCC
Barbara Burtness
7:03
Pembrolizumab for frontline head and neck cancer: KEYNOTE-048 results
Barbara Burtness • 22 Oct 2018
0:58
Checkpoint inhibitors for head and neck cancer in the definitive setting?
Barbara Burtness
7:56
KEYNOTE-048: progression post next line for R/M HNSCC
Barbara Burtness • 28 May 2020

Related Videos

6:20
EPIC-OPC: testing for only p16 can lead to oropharyngeal cancer misclassification
Miren Taberna • 23 Sep 2020
2:12
Thyroid cancer studies at ESMO 2020
Enrique Grande • 18 Sep 2020
1:40
Anti-PD-L1/TGF-β trap in non-HPV associated HNSCC
Jason Redman • 24 Jun 2020
4:23
Speech & swallowing problems after head and neck cancer
Justin Roe • 9 Jun 2020
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals